Use of synthetic cannabinoids in patients with psychotic disorders: Case series

Journal of Dual Diagnosis

Volumn 10, Issue 3, 2014, Pages 168-173

  Celofiga, Andreja ^a   Koprivsek, Jure ^a   Klavz, Janez ^a  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

AM 2201; detection; intoxication; long term consequences; paranoid schizophrenia; substance use; synthetic cannabinoids

Indexed keywords

1-((5-FLUOROPENTYL)-1H-INDOL-3-YL)-(NAPHTHALEN-1-YL)METHANONE; INDOLE DERIVATIVE; NAPHTHALENE DERIVATIVE; PSYCHOTROPIC AGENT; STREET DRUG;

ADULT; CASE REPORT; CHEMISTRY; COMPLICATION; GAS CHROMATOGRAPHY; HOSPITALIZATION; HUMAN; MALE; MASS SPECTROMETRY; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

ADULT; CHROMATOGRAPHY, GAS; HOSPITALIZATION; HUMANS; INDOLES; MALE; MASS SPECTROMETRY; NAPHTHALENES; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84905822337     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1080/15504263.2014.929364     Document Type: Conference Paper

References (20)

1. Auwarter, V., Dresen, S., Weinmann, W., Muller, M., Putz, M., & Ferreiros, N. (2009). 'Spice' and other herbal blends: Harmless incense or cannabinoid designer drugs? Journal of Mass Spectrometry, 44(5), 832-837. doi:10.1002/jms.1558
2. EMCDDA. (2009). Understanding the 'Spice' phenomenon. http://www.emcdda.europa.eu/publications/thematic-papers/spice
3. EMCDDA. (2013). Synthetic cannabin oids in Europe. http://www.emcdda. europa.eu/topics/pods/synthetic-cannabinoids
4. Every-Palmer, S. (2011). Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug and Alcohol Dependence, 117(2- 3), 152-157. doi:10.1016/j.drugalcdep.2011.01.012
5. Forrester, M. B., Kleinschmidt, K., Schwarz, E., & Young, A. (2011). Synthetic cannabinoid exposures reported to Texas poison centers. Journal of Addictive Diseases , 30(4), 351-358. doi:10.1080/10550887.2011.609807
6. Harris C. R. Brown A. 2013 Synthetic cannabinoid intoxication: A case series and review. Journal of Emergency Medicine 44(2), 360-366 doi:10.1016/j.jemermed.2012.07.061
7. Huffman, J.W.,&Lainton, J. A. (1996).Recent developments in themedicinal chemistry of cannabinoids. Current Medicinal Chemistry, 3, 101-116.
8. Huffman, J. W., Mabon, R., Wu, M. J., Lu, J., Hart, R., Hurst, D. P.,, & Martin, B. R. (2003). 3-indolyl-1-naphthylmethanes: New cannabimimetic indoles provide evidence for aromatic stacking interactions with the cb1 cannabinoid receptor. Bioorganic & Medicinal Chemistry, 11, 539-549. doi:10.1016/S0968-0896(02)00451-0
9. Kneisel, S., Westphal, F., Bisel, P., Brecht, V., Broeckerd, S., & Auwart era, V. (2012). Identification and structural characterization of the synthetic cannabinoid 3-(1-adamantoyl)-1-pentylindole as an additive in 'herbal incense'. Journal of Mass Spectrometry, 47, 195-200. doi:10.1002/jms. 2059
10. Lapoint, J., James, L. P.,Moran,C. L., Nelson, L. S., Hoffman, R. S.,.& Moran, J. H. (2011). Severe toxicity following synthetic cannabinoid ingestion. Clinical Toxicology, 49(8), 760-764. doi:10.3109/15563650. 2011.609822
11. Lindigkeit, R., Boehme, A., Eiserloh, I., Luebbecke, M., Wiggermann, M., Ernst, L., & Beuerle, T. (2009). Spice: A never ending story? Forensic Science International, 191(1 -3), 58-63. doi:10.1016/j.forsciint.2009.06.008
12. McQuade, D., Hudson, S., Dargan, P. I.,&Wood, D. M. (2013). First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid rece ptor agonist AM-2201. European Journal of Clinical Pharmacology, 69(3), 373-376. doi:10.1007/s00228-012-1379-2
13. Moller, I., Wintermeyer, A., Bender, K., Jubner, M., Thomas, A., Krug, O., , & Thevis, M. (2011). Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Testing and Analysis, 3(9), 609-620. doi:10.1002/dta.158
14. Moosmann, B., Kneisel , S., Girreser, U., Brecht, V., Westphal, F., & Auwarter, V. (2012). Separation and structural characterization of the synthetic cannabinoids JWH-412 and 1-[(5-fluoropentyl)-1H-indol-3yl]-(4- methylnaphthalen-1-yl)methanone using G C-MS, NMR analysis and a flash chromatography system. Forensic Science International, 220(1- 3), 17-22. doi:10.1016/j.forsciint.2011.12.010
15. Rodriguez, M. L. (2013). Consolidating the screening of synthetic cannabinoids using antibody based assays with a broad specificity profile. TIAFT Bulletin, 43(1), 22-23.
16. Schneir, A. B., & Baumbacher, T. (2012). Convulsions associated with the use of a synthetic cannabinoid product. Journal of Medical Toxicology, 8(1), 62-64. doi:10.1007/s13181-011-0182-2
17. Schaefer, N., Peters, B., Bregel, D., Kneisel, S., Auwarter, V., Schmidt, P. H., & Ewald, A. H. (2013). A fa tal case involving several synthetic cannabinoids. Toxikologische und Forensische Chemie, 80(Special Issue), 248-251.
18. Sobolevsky, T., Prasolov, I., & Rodchenkov, G. (2012). Detection of urinary metabolites of AM -2201 and UR-144, two novel synthetic cannabinoids. Drug Testing and Analysis. Special Issue: Advances in Sports Drug Testing, 4(10), 745-753. doi:10.1002/dta.1418
19. Uchiyama, N., Kawamura, M., Kikura-Hanajiri, R., & Goda, Y. (2011). Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl- 1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3- carboxamide (APINACA), and detection of five synthetic cannabinoids, A M-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicology, 30(2), 114-125. doi:10.1007/s11419-012-0136-7
20. Vardakou, I., Pistos, C., & Spiliopoulou, C. ( 2010). Spice drugs as a new trend: Mode of action, identification and legislation. Toxicology Letters, 197(3), 157-162. doi:10.1016/j.toxlet.2010.06.00